Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer (Q37630362)

21 August 2017

1 reference

title

Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

S J Freedland

1

1 reference

PubMed ID

19901933

21 August 2017

J Eastham

series ordinal

2

1 reference

PubMed ID

19901933

21 August 2017

N Shore

series ordinal

3

1 reference

21 August 2017

1 September 2009

1 reference

Prostate Cancer and Prostatic Diseases

21 August 2017

1 reference

21 August 2017

12

1 reference

21 August 2017

4

1 reference

21 August 2017

333-338

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2009.35

21 August 2017

0 references

cites work

Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

The role of aromatization in testosterone supplementation: effects on cognition in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

The treatment of prostate cancer: an overview of current options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Androgen receptor in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Androgen deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Management of the side effects of androgen deprivation therapy in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

The current state of hormonal therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

New developments in the pathogenesis and treatment of steroid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Bone mineral density in elderly men and women: results from the Framingham osteoporosis study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Risk of fracture after androgen deprivation for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Fracture risk in Danish men with prostate cancer: a nationwide register study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Pathophysiology and treatment of hot flashes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Impact of Event Scale: A Measure of Subjective Stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Complications of androgen-deprivation therapy in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Gynecomastia in patients with prostate cancer: update on treatment options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

The protective effects of estrogen on the cardiovascular system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Testosterone loss and estradiol administration modify memory in men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Estradiol and cognition during androgen deprivation in men with prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Associations between serum testosterone fall and cognitive function in prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Bone health in men receiving androgen deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Androgen deprivation therapy for prostate cancer: current status and future prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.35

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.35

1 reference

21 August 2017

1 reference

PubMed ID

19901933